CELL & GENE THERAPY - It’s Time to Build Infrastructure to Handle the Coming Surge

Fran Gregory says the complexities and innovations associated with the production of cell and gene therapies also necessitates a shift in infrastructure, which will affect manufacturers, distributors, and providers. From development, manufacturing, storage, and delivery to patients; each step in the process requires forging a new path.

EXCLUSIVE WHITEPAPERS

EXCLUSIVE WEBINARS

EXCLUSIVE ONLINE CONTENT